Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

BioForward 2025

BioForward is a dynamic one-day exhibition designed specifically for life sciences service providers and suppliers. Tailored for R&D SMEs, the event offers a unique opportunity [...]

Go to Top